BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21446046)

  • 1. Is resection of colorectal liver metastases after a second-line chemotherapy regimen justified?
    Brouquet A; Overman MJ; Kopetz S; Maru DM; Loyer EM; Andreou A; Cooper A; Curley SA; Garrett CR; Abdalla EK; Vauthey JN
    Cancer; 2011 Oct; 117(19):4484-92. PubMed ID: 21446046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
    Reddy SK; Broadwater G; Niedzwiecki D; Barbas AS; Hurwitz HI; Bendell JC; Morse MA; Clary BM
    J Gastrointest Surg; 2009 Jan; 13(1):74-84. PubMed ID: 18685900
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases.
    Shindoh J; Loyer EM; Kopetz S; Boonsirikamchai P; Maru DM; Chun YS; Zimmitti G; Curley SA; Charnsangavej C; Aloia TA; Vauthey JN
    J Clin Oncol; 2012 Dec; 30(36):4566-72. PubMed ID: 23150701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative chemotherapy does not increase morbidity or mortality of hepatic resection for colorectal cancer metastases.
    Scoggins CR; Campbell ML; Landry CS; Slomiany BA; Woodall CE; McMasters KM; Martin RC
    Ann Surg Oncol; 2009 Jan; 16(1):35-41. PubMed ID: 18987915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
    Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
    Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases.
    Blazer DG; Kishi Y; Maru DM; Kopetz S; Chun YS; Overman MJ; Fogelman D; Eng C; Chang DZ; Wang H; Zorzi D; Ribero D; Ellis LM; Glover KY; Wolff RA; Curley SA; Abdalla EK; Vauthey JN
    J Clin Oncol; 2008 Nov; 26(33):5344-51. PubMed ID: 18936472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
    Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
    Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What is a safe future liver remnant size in patients undergoing major hepatectomy for colorectal liver metastases and treated by intensive preoperative chemotherapy?
    Narita M; Oussoultzoglou E; Fuchshuber P; Pessaux P; Chenard MP; Rosso E; Nobili C; Jaeck D; Bachellier P
    Ann Surg Oncol; 2012 Aug; 19(8):2526-38. PubMed ID: 22395987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perioperative chemotherapy with bevacizumab and liver resection for colorectal cancer liver metastasis.
    Chaudhury P; Hassanain M; Bouganim N; Salman A; Kavan P; Metrakos P
    HPB (Oxford); 2010 Feb; 12(1):37-42. PubMed ID: 20495643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome.
    Poultsides GA; Bao F; Servais EL; Hernandez-Boussard T; DeMatteo RP; Allen PJ; Fong Y; Kemeny NE; Saltz LB; Klimstra DS; Jarnagin WR; Shia J; D'Angelica MI
    Ann Surg Oncol; 2012 Sep; 19(9):2797-804. PubMed ID: 22476753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression while receiving preoperative chemotherapy should not be an absolute contraindication to liver resection for colorectal metastases.
    Viganò L; Capussotti L; Barroso E; Nuzzo G; Laurent C; Ijzermans JN; Gigot JF; Figueras J; Gruenberger T; Mirza DF; Elias D; Poston G; Letoublon C; Isoniemi H; Herrera J; Sousa FC; Pardo F; Lucidi V; Popescu I; Adam R
    Ann Surg Oncol; 2012 Sep; 19(9):2786-96. PubMed ID: 22622469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histological response, pattern of tumor destruction and clinical outcome after neoadjuvant chemotherapy including bevacizumab or cetuximab in patients undergoing liver resection for colorectal liver metastases.
    Stremitzer S; Stift J; Singh J; Starlinger P; Gruenberger B; Tamandl D; Gruenberger T
    Eur J Surg Oncol; 2015 Jul; 41(7):868-74. PubMed ID: 25865557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
    Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
    Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Consequences of chemotherapy on resection of colorectal liver metastases.
    Pessaux P; Chenard MP; Bachellier P; Jaeck D
    J Visc Surg; 2010 Aug; 147(4):e193-201. PubMed ID: 20655821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic resection after rescue cetuximab treatment for colorectal liver metastases previously refractory to conventional systemic therapy.
    Adam R; Aloia T; Lévi F; Wicherts DA; de Haas RJ; Paule B; Bralet MP; Bouchahda M; Machover D; Ducreux M; Castagne V; Azoulay D; Castaing D
    J Clin Oncol; 2007 Oct; 25(29):4593-602. PubMed ID: 17925554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regenerative nodular hyperplasia of the liver related to chemotherapy: impact on outcome of liver surgery for colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Ciacio O; Lévi F; Paule B; Giacchetti S; Guettier C; Azoulay D; Castaing D; Adam R
    Ann Surg Oncol; 2011 Mar; 18(3):659-69. PubMed ID: 20976564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant chemotherapy with FOLFOX for primary colorectal cancer is associated with increased somatic gene mutations and inferior survival in patients undergoing hepatectomy for metachronous liver metastases.
    Andreou A; Kopetz S; Maru DM; Chen SS; Zimmitti G; Brouquet A; Shindoh J; Curley SA; Garrett C; Overman MJ; Aloia TA; Vauthey JN
    Ann Surg; 2012 Oct; 256(4):642-50. PubMed ID: 22968062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.